Early-stage ALK-positive lung cancer: a narrative review
Translational Lung Cancer Research · 2023-02 · 12 (2) · 337-345
DOI: 10.21037/tlcr-22-631 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Lung Cancer Research, 2023-02. Verfasst von Monica F Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical…. Die Arbeit wurde bisher 36-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background and Objective: While anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are standard of care treatment for metastatic ALK-positive non-small cell lung cancer (NSCLC), the benefit of moving ALK inhibitors to earlier disease stages is unclear. The objective of this review is to summarize the literature regarding the prevalence and prognosis of early-stage ALK-positive NSCLC and the utility of targeted therapies, immunotherapy, and chemotherapy in the neoadjuvant and adjuvant settings.
Methods
We identified the references for this narrative review through a literature search of papers about early stage ALK-positive NSCLC using PubMed and clinicaltrials.gov. Last search was run on July 3, 2022. There were no language or time frame restrictions. Key Content and Findings: The incidence of oncogenic ALK alterations in early-stage NSCLC ranges from 2-7%, and ALK-positive NSCLC patients are more likely to be younger and never or light smokers. Studies on the prognostic impact of ALK in early-stage disease have had conflicting results. ALK TKIs are not approved in the neoadjuvant or adjuvant setting and there is a lack of large, randomized trial results. Several trials are currently accruing but results are not expected for several years.
Conclusions
Attempts at large, randomized trials to evaluate the benefit of ALK TKIs in the adjuvant and neoadjuvant has been hampered by slow recruitment given the rarity of ALK alterations, lack of universal genetic testing, and the rapid pace of drug development. Expanded lung cancer screening recommendations, liberalization of surrogate endpoints (i.e., pathological complete response and major pathological response), growth of multicenter national clinical trials, and new diagnostic technologies (i.e., cell-free DNA liquid biopsies) provide hope of generating much needed data to definitively answer the question of the utility of ALK-directed therapies in the early-stage setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Chen, M. F., & Chaft, J. E. (2023). Early-stage ALK-positive lung cancer: a narrative review. Translational Lung Cancer Research, 12(2), 337-345. https://doi.org/10.21037/tlcr-22-631
Vancouver
Chen MF, Chaft JE. Early-stage ALK-positive lung cancer: a narrative review. Translational Lung Cancer Research. 2023;12(2):337-345. doi:10.21037/tlcr-22-631
BibTeX
@article{Chen2023,
author = {Chen, Monica F and Chaft, Jamie E},
title = {Early-stage ALK-positive lung cancer: a narrative review},
journal = {Translational Lung Cancer Research},
year = {2023},
volume = {12},
number = {2},
pages = {337--345},
doi = {10.21037/tlcr-22-631}
}
EUVIMED